Gilead Sciences Updates Passive Stake in Tango Therapeutics

TL;DR

**Gilead still owns Tango stock, signaling continued interest.**

AI Summary

Gilead Sciences, Inc. filed an amended SC 13G/A on February 13, 2024, indicating its ownership of Tango Therapeutics, Inc. common stock as of December 31, 2023. This filing updates previous disclosures, confirming Gilead's continued significant, though passive, stake in Tango Therapeutics. For investors, this means a major pharmaceutical company maintains an interest in Tango, potentially signaling confidence in its long-term prospects or ongoing collaboration, which could influence stock stability.

Why It Matters

This filing confirms Gilead's continued, albeit passive, investment in Tango Therapeutics, which can be seen as a vote of confidence from a major pharmaceutical player, potentially stabilizing Tango's stock.

Risk Assessment

Risk Level: low — This is an amendment to a passive ownership filing, indicating no immediate change in control or significant new risk.

Analyst Insight

Investors should note Gilead's continued passive stake in Tango Therapeutics, which could be a positive signal, but this filing alone doesn't suggest any immediate catalysts or changes in operational strategy for either company.

Key Players & Entities

• Gilead Sciences, Inc. (company) — the reporting person and investor in Tango Therapeutics
• Tango Therapeutics, Inc. (company) — the subject company in which Gilead Sciences holds shares
• December 31, 2023 (date) — the date of the event requiring this filing
• 87583X109 (other) — the CUSIP number for Tango Therapeutics' Common Stock

FAQ

From the Filing

0001193125-24-033887.txt : 20240213 0001193125-24-033887.hdr.sgml : 20240213 20240213165100 ACCESSION NUMBER: 0001193125-24-033887 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Tango Therapeutics, Inc. CENTRAL INDEX KEY: 0001819133 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-92241 FILM NUMBER: 24626997 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 901 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (857) 320-4900 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 901 CITY: BOSTON STATE: MA ZIP: 02215 FORMER COMPANY: FORMER CONFORMED NAME: BCTG Acquisition Corp. DATE OF NAME CHANGE: 20200723 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 SC 13G/A 1 d756953dsc13ga.htm SC 13G/A SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TANGO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☒ Rule 13d-1(c) ☐ Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 87583X109  1   N AME OF R EPORTING P E RSON  Gilead Sciences, Inc.  2  C HECK THE A PPROPRIATE B OX IF A M EMBER OF A G ROUP (S EE I NSTRUCTIONS )  (a) ☐  (b) ☐  3  SEC U SE O NLY  4  C ITIZENSHIP OR P LACE OF O RGANIZATION  Delaware NUMBER OF SHARES  BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH 5   S OLE V OTING P OWER  4,854,443 6  S HARED V OTING P OWER  0 7  S OLE D ISPOSITIVE P OWER  4,854,443 8  S HARED D ISPOSITIVE P OWER  0  9   A GGREGATE A MOUNT B ENEFICIALLY O WNED BY E ACH R EPORTING P ERSON  4,854,443 10  C HECK IF THE A GGREGATE A MOUNT IN R OW (9) E XCLUDES C ERTAIN S HARES (S EE I NSTRUCTIONS )  ☐ 11  P ERCENT OF C LASS R EPRESENTED BY A MOUNT IN R OW (9)  4.8% (1) 12  T YPE OF R EPORTING P ERSON (S EE I NSTRUCTIONS )  CO (1) Percentage based on 101,989,696 shares of Common Stock outstanding as of November 1, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q (“Form 10-Q”) filed with the U.S. Securities and Exchange Commission (“SE